Global Information
회사소개 | 문의 | 비교리스트

세계의 심혈관질환 치료제 시장 조사 및 예측

Global Cardiovascular Drug Market Research and Forecast 2018-2023

리서치사 Orion Market Research Pvt Ltd
발행일 2018년 07월 상품 코드 670574
페이지 정보 영문
가격
US $ 3,600 ₩ 4,313,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,751,000 Printable PDF (Enterprise License)


세계의 심혈관질환 치료제 시장 조사 및 예측 Global Cardiovascular Drug Market Research and Forecast 2018-2023
발행일 : 2018년 07월 페이지 정보 : 영문

세계의 심혈관질환 치료제(Cardiovascular Drug) 시장에 대해 조사했으며, 시장 현황과 성장 예측, 약제별·질환별·유통 채널별·지역별 동향, 시장 진출기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 보고서 요약

제2장 시장 개요와 인사이트

  • 정의
  • 애널리스트 인사이트와 현재 시장 동향
  • 규제

제3장 시장 결정요인

  • 성장 촉진요인
  • 성장 저해요인
  • 기회

제4장 시장 세분화

  • 약제 종류별
    • 항혈전제
    • 항고지혈증제
    • 베타차단제
    • 칼슘채널 차단제
    • 이뇨제
    • 레닌-안지오텐신 시스템 차단제
    • 기타
  • 질환별
    • 부정맥
    • 관상동맥질환
    • 고지혈증
    • 고혈압
    • 말초동맥질환
  • 유통 채널별
    • 원내 약국
    • 온라인 약국
    • 소매 약국

제5장 경쟁 환경

  • 주요 전략
  • 기업 분석

제6장 지역별 분석

  • 북미
  • 유럽
  • 아시아태평양
  • 기타

제7장 기업 개요

LSH 18.08.14

List of Tables

  • TABLE # 1 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE 2017-2023($ MILLION).
  • TABLE # 2 GLOBAL ANTI-CLOTTING AGENTS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 3 GLOBAL ANTIHYPERLIPIDEMIC MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 4 GLOBAL BETA BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 5 GLOBAL CALCIUM CHANNEL BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 6 GLOBAL DIURETICS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 7 GLOBAL RENIN-ANGIOTENSIN SYSTEM BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 8 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE 2017-2023($ MILLION).
  • TABLE # 9 GLOBAL ARRHYTHMIA MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 10 GLOBAL CORONARY ARTERY DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
  • TABLE # 11 GLOBAL HYPERLIPIDEMIA MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 12 GLOBAL HYPERTENSION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 13 GLOBAL PERIPHERAL ARTERY DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 14 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
  • TABLE # 15 GLOBAL HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 16 GLOBAL ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 17 GLOBAL RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
  • TABLE # 18 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
  • TABLE # 19 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
  • TABLE # 20 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
  • TABLE # 21 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
  • TABLE # 22 NORTH AMERICA S MART PARKING MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
  • TABLE # 23 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
  • TABLE # 24 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
  • TABLE # 25 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
  • TABLE # 26 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
  • TABLE # 27 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
  • TABLE # 28 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
  • TABLE # 29 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
  • TABLE # 30 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
  • TABLE # 31 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
  • TABLE # 32 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
  • TABLE # 33 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
  • TABLE # 34 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION)
  • TABLE # 35 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION)
  • TABLE # 36 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION)
  • TABLE # 37 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY DRUG TYPE2017 VS 2023(IN %)
  • FIGURE # 2 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY DISEASE TYPE 2017 VS 2023(IN %)
  • FIGURE # 3 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY DISTRIBUTION CHANNEL 2017 VS 2023(IN %)
  • FIGURE # 4 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
  • FIGURE # 5 UNITED STATES CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
  • FIGURE # 6 CANADA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
  • FIGURE # 7 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 8 UK CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 9 GERMANY CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 10 SPAIN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 11 FRANCE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 12 ITALY CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 13 REST OF EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 14 ASIA PACIFIC REGION CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 15 INDIA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 16 CHINA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 17 JAPAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 18 REST OF ASIA PACIFIC REGION CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • FIGURE # 19 REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)

Cardiovascular disease (CVD) involves heart and blood vessel blockage which leads to heart attack, chest pain and other heart problems. It is one of the leading cause of death worldwide. CVD mainly caused due to high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol consumption. Factors motivating the growth of CVD drug market includes increasing geriatric population and changing lifestyle such as shift in work hours. Advancement in cardiovascular diagnosis procedure and technological improvement in the healthcare have fuelled the growth of this market. Growing healthcare expenditure in emerging economies and cost-effective and affordable cardiovascular solution by leading manufacturers have provided new opportunity to this market.

Geographically, Cardiovascular drug market is divided into North America, Europe, Asia Pacific and Rest of the World. In terms of revenue generation North America region represents the largest market for cardiovascular drugs. Adoption of genetic engineering in U.S for diagnosis of cardiovascular diseases is another driving factor. Increasing government funding to improve healthcare infrastructure, and rising awareness about cardiovascular drug are the major factor which drives this market in APAC region.

The global players in the cardiovascular drug market include Abbott laboratories, Bristol-Myers Squibb company, Sanofi, Boston scientific, C.R bard. The strategy adopted in these companies are continuous investments in (R&D) which made them progress over the past several years in offering better drug with minimum side effects. As a result, market player may offer low-cost, high-value solutions and services to various community hospitals and clinics. In January 2018, Sanofi acquired Ablynx to expand their product portfolio for rare blood disorders and continue to advance the strategic transformation for drug discovery.

Research Methodology

The market study of Global Cardiovascular drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Authentic Public Databases such as the FDA, WHO and others
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalogue.

The Report is intended for cardiovascular drug manufacturers, cardiovascular drug API manufacturer, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating in delivering insights into the market for better business decisions.

The Report covers:

  • Comprehensive research methodology of Global Cardiovascular drug market.
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Cardiovascular drug market.
  • Insights about market determinants which are stimulating the Global Cardiovascular drug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATION
      • 2.3.1.1. UNITED STATES
      • 2.3.1.2. EUROPEAN UNION
      • 2.3.1.3. CHINA
      • 2.3.1.4. INDIA

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. INCREASING ENVIRONMENTAL POLLUTION, EXCESSIVE ALCOHOL CONSUMPTION & SMOKING.
    • 3.1.2. CHANGING LIFESTYLE & SHIFTS IN WORK HOURS.
    • 3.1.3. TECHNOLOGICAL ADVANCEMENT IN HEALTHCARE.
    • 3.1.4. INCREASING HEALTHCARE EXPENDITURE IN DEVELOPING NATION.
  • 3.2. RESTRAINT
    • 3.2.1. HIGH MEDICATION COST.
    • 3.2.2. STRICT GOVERNMENTAL REGULATION FOR DRUG APPROVAL.
  • 3.3. OPPORTUNITY
    • 3.3.1. ADOPTION OF GENETIC ENGINEERING FOR DIAGNOSIS PROCEDURE.
    • 3.3.2. INCREASE IN R&D SPENDING BY PHARMACEUTICAL COMPANIES FOR DRUG DISCOVERY.

4. MARKET SEGMENTATION

  • 4.1. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DRUG TYPE
    • 4.1.1. ANTI-CLOTTING AGENTS
    • 4.1.2. ANTIHYPERLIPIDEMIC
    • 4.1.3. BETA BLOCKERS
    • 4.1.4. CALCIUM CHANNEL BLOCKERS
    • 4.1.5. DIURETICS
    • 4.1.6. RENIN-ANGIOTENSIN SYSTEM BLOCKERS
    • 4.1.7. OTHER
  • 4.2. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DISEASE
    • 4.2.1. ARRHYTHMIA
    • 4.2.2. CORONARY ARTERY DISEASE
    • 4.2.3. HYPERLIPIDEMIA
    • 4.2.4. HYPERTENSION
    • 4.2.5. PERIPHERAL ARTERY DISEASE
  • 4.3. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DISTRIBUTION CHANNEL
    • 4.3.1. HOSPITAL PHARMACY
    • 4.3.2. ONLINE PHARMACY
    • 4.3.3. RETAIL PHARMACY

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
  • 5.2. KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. UK
    • 6.2.2. GERMANY
    • 6.2.3. SPAIN
    • 6.2.4. FRANCE
    • 6.2.5. ITALY
    • 6.2.6. REST OF EUROPE
  • 6.3. APAC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
    • 6.3.4. REST OF APAC
  • 6.4. REST OF THE WORLD

7. COMPANY PROFILES

  • 7.1. ABBOTT LABORATORIES
  • 7.2. AMGEN
  • 7.3. BAYER AG
  • 7.4. BOEHRINGER INGELHEIM
  • 7.5. BRISTOL-MYERS SQUIBB COMPANY
  • 7.6. C. R. BARD, INC.
  • 7.7. COOK MEDICAL
  • 7.8. DAIICHI SANKYO CO LTD
  • 7.9. ELI LILLY AND COMPANY
  • 7.10. F. HOFFMANN-LA ROCHE LTD.
  • 7.11. GILEAD SCIENCES
  • 7.12. GLAXOSMITHKLINE
  • 7.13. JOHNSON & JOHNSON
  • 7.14. KPI HEALTHCARE INC
  • 7.15. MERCK & CO. INC.
  • 7.16. NOVARTIS AG
  • 7.17. OTSUKA HOLDINGS CO., LTD.
  • 7.18. PFIZER
  • 7.19. SANOFI
  • 7.20. TAKEDA PHARMACEUTICALS COMPANY LIMITED
Back to Top
전화 문의
F A Q